MGMT promoter methylation and consequently low MGMT expression is typical in, but not unique to IDH1 mutant gliomas [12], which generally respond better to TMZ than their IDH1 wild type (WT) counterparts [13, 14]. The gene discussed is MGMT; the disease is central nervous system cancer.